While Immune Checkpoint Inhibitor (ICI) immunotherapy drugs have transformed the treatment of many cancers, some lung cancer patients experience hyperprogression—a paradoxical rapid acceleration of tumor growth—after ...
Apr 28, 2023
0
13
Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer, and the leading cause of cancer death worldwide. More than half of NSCLC patients die after developing metastases. There are no tests currently that ...
Mar 11, 2020
0
145
The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leading to mesenchymal-epithelial ...
Aug 15, 2022
0
6
Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous ...
Feb 7, 2020
0
1
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases ...
Mar 9, 2021
0
32
The majority of lung cancers are classified as non-small cell lung cancer (NSCLC). Even with early detection, the 5-year survival rate for patients with NSCLC is less that 50%. Compared to the surrounding tissue, cancer cells ...
Jan 20, 2015
0
13
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented ...
Dec 7, 2017
0
1
The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3 - 7 cm.
Jun 13, 2016
0
4
Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
1
Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched ...
Aug 22, 2014
0
1
